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Abstract
Background: Previously assumed to be a select ligand for chemokine receptor CXCR4, chemokine CXCL12 is now
known to activate both CXCR4 and CXCR7. However, very little is known about the co-expression of these
receptors in cancer cells.
Methods: We used immunohistochemistry to determine the extent of co-expression in pancreatic cancer tissue
samples and immunoblotting to verify expression in pancreatic cancer cell lines. In cell culture studies, siRNA was
used to knock down expression of CXCR4, CXCR7, K-Ras and b-arrestin -2 prior to stimulating the cells with
CXCL12. Activation of the mitogen-activated protein kinase pathway (MAPK) was assessed using both a Raf-pull
down assay and western blotting. The involvement of the receptors in CXCL12-mediated increases in cell
proliferation was examined via an ATP-based proliferation assay.
Results: First, we discovered frequent CXCR4/CXCR7 co-expression in human pancreatic cancer tissues and cell
lines. Next, we observed consistent increases in ERK1/2 phosphorylation after exposure to CXCL12 or CXCL11, a
CXCR7 agonist, in pancreatic cancer cell lines co-expressing CXCR4/CXCR7. To better characterize the receptor-
mediated pathway(s), we knocked down CXCR4 or CXCR7, exposed the cells to CXCL12 and examined
subsequent effects on ERK1/2. We observed that CXCR7 mediates the CXCL12-driven increase in ERK1/2
phosphorylation. Knockdown of CXCR4 expression however, decreased levels of K-Ras activity. Conversely, KRAS
knockdown greatly reduced CXCL12-mediated increases in ERK1/2 phosphorylation. We then evaluated the role
of b-arrestin-2, a protein directly recruited by chemokine receptors. We observed that b-arrestin-2 knockdown
also inhibited increases in ERK1/2 phosphorylation mediated by both CXCR4 and CXCR7. Finally, we investigated
the mechanism for CXCL12-enhanced cell proliferation and found that either receptor can modulate cell
proliferation.
Conclusions: In summary, our data demonstrate that CXCR4 and CXCR7 are frequently co-expressed in human
pancreatic cancer tissues and cell lines. We show that b-arrestin-2 and K-Ras dependent pathways coordinate the
transduction of CXCL12 signals. Our results suggest that the development of therapies based on inhibiting CXCL12
signaling to halt the growth of pancreatic cancer should be focused at the ligand level in order to account for the
contributions of both receptors to this signaling pathway.
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It is well-established that chemokines interact with G
protein-coupled receptors (GPCRs) to activate down-
stream signaling pathways that enhance cancer cell
growth, migratory behavior, and cell survival [1,2]. Pre-
vious studies have characterized the effects of chemo-
kine CXCL12 in many cancers [3-5] including its role in
promoting local invasion and distant metastasis of pan-
creatic cancer [4,6-8]. Its corresponding receptor
CXCR4 has been widely investigated initially because
reports showed it is a co-receptor for T-tropic HIV-1
and HIV-2 entry into CD4
+ cells [9,10]. Since then,
CXCL12 was found to be the specific ligand for CXCR4
[11,12]. As such, the CXCL12-CXCR4 axis has been the
focus of research into therapeutic strategies for pancrea-
tic and other cancers [7,13-15]. Recent data, however,
shows that CXCL12 also binds to and activates chemo-
kine receptor CXCR7 [16-19]. Therefore, downstream
cell functions, which have been previously attributed to
CXCR4, may also result from CXCR7-mediated
signaling.
CXCR7 is expressed in many different tissues, includ-
ing neurons, immune cells, and endothelial cells; recep-
tor-mediated signaling can occur by binding one of its
two known ligands, CXCL11 or CXCL12 [17,18,20,21].
It has a dedicated role in fetal cardiac development and
B-cell localization as elucidated in CXCR7-deficient
mice [17,18,20,21]. As with many other chemokine
receptors, CXCR7 is known to induce oncogenic pheno-
types apart from its innate role in organogenesis and
immunity [17,18,20,21]. Similar to what is known about
CXCR4, recent reports have indicated that CXCR7 pro-
motes cancer cell survival through anti-apoptotic
mechanisms [17,22]. However, in contrast to the down-
stream effects of CXCR4, chemotaxis has not been
reported to be induced by CXCR7-mediated signaling
[17]. Although these data may suggest divergent func-
tions for CXCR4 and CXCR7 in cancer cells, little is
known regarding the frequency of co-expression and
therein the mechanism for propagation of CXCL12
signals.
We previously investigated CXCL12 signaling in pan-
creatic cancer cells and observed enhanced cell prolif-
eration mediated by the MAPK pathway [23,24]. Here,
our objective was to investigate the roles of CXCR4 and
CXCR7 in CXCL12-driven activation of the MAPK
pathway in human pancreatic cancer cells. We examined
b-arrestins which are recruited by GPCRs [25], as well
as K-Ras, which is known to regulate the MAPK path-
way [26]. Our results demonstrate that CXCR4 and
CXCR7 are co-expressed with high frequency in human
pancreatic cancers and that either receptor can regulate
the MAPK pathway. Our results suggest that both
CXCR4 and CXCR7 are potential targets in the develop-
ment of effective therapies to halt the growth of pan-
creatic cancer.
Materials and methods
Cell culture and reagents
Human pancreatic cancer cell lines AsPC-1, MiaPaCa-2,
PANC-1, SU.86.86, HS-766 T and BxPC-3,were obtained
from American Type Culture Collection (ATCC; Mana-
ssas, VA) within the past 5 years. FG cells, which are a
metastatic derivative of the pancreatic adenocarcinoma
cells COLO-357, were provided by Dr. A. Lowy. All
cells used for the experiments presented in this study
were immediately cryopreserved in liquid nitrogen after
they were obtained. All cell lines were assessed by DNA
extraction, polymerase chain reaction (PCR) amplifica-
tion, and sequencing for KRAS and TP53 gene muta-
tions to verify the genotype of cells (data not shown).
Cells were maintained in ATCC-recommended media at
37°C and 5% CO2. Serum-starvation lasted for 12-24 h
unless otherwise noted.
CXCL12 and epidermal growth factor (EGF) were pur-
chased from Peprotech (Rocky Hill, NJ); CXCL11and
CXCL10 from R&D Systems (Minneapolis, MN). The
following antibodies were used: rabbit polyclonal antibo-
dies against phospho-ERK1/2 and total ERK1/2 (Cell
Signaling; Beverly, MA), rabbit polyclonal antibodies
against CXCR4 (Abcam, Cambridge, MA) and CXCR7
(Abcam and R&D Systems), a goat polyclonal antibody
against b-arrestin-2 (Abcam), and a mouse monoclonal
antibody against K-Ras (Calbiochem; San Diego, CA).
Immunoblotting
Cell lysates were collected as previously described [27].
Twenty micrograms of protein were separated on 12%
SDS-polyacrylamide gels and transfered onto PVDF
membranes (Millipore; Bedford, MA). The membranes
were blocked for 1 h and probed overnight with primary
antibodies. After washing, membranes were labeled with
horseradish peroxidase (HRP)-conjugated secondary
antibodies (BioRad; Hercules, CA). Blots were developed
with a chemiluminescence substrate (Amersham Phar-
macia; Piscataway, NJ) and imaged.
Tissue staining
We assessed CXCR4 and CXCR7 expression in forma-
lin-fixed paraffin embedded (FFPE) specimens as pre-
viously described [27]. Pancreatic cancers were
obtained from patients who had undergone resection
for pancreatic adenocarcinoma with Institutional
Review Board approval. Tissue blocks were sectioned
(5 μm) and deparaffinized with xylene. After antigen
retrieval was performed, a section was incubated with
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section from the tissue block was incubated with the
anti-CXCR7 antibody. Then, they were labeled with
secondary antibody (EnVision Plus; Dako, Carpinteria,
CA), developed, and examined under microscopy at
200× magnification.
Short interfering RNA (SiRNA)
Pancreatic cancer cells were transfected with siRNA
(100 nM) using RNAiMAX (Invitrogen; Carlsbad, CA)
according to the manufacturer’s instructions and incu-
bated for 48 h prior to application of treatments. siR-
N A su s e dw e r ec o n t r o l ,C X C R 4 ,C X C R 7 ,b-arrestin-2
and KRAS (Dharmacon; Lafayette, CO).
K-ras activity
K-Ras activity was measured by a Raf pull-down assay
(Millipore). In this enzyme-linked immunosorbent assay,
cells maintained in serum-free media, were exposed to
CXCL12 (100 ng/ml) or CXCL11 (200 ng/ml) for 15
min and then lysed. The cell lysate (100 μg) was incu-
bated with Raf-1 Ras Binding Domain (RBD)-agarose.
K-Ras proteins captured by Raf-1-RBD were detected
and measured by the addition of an anti-K-Ras antibody
(Millipore). An HRP-conjugated secondary antibody was
then added. After adding a chemiluminescent substrate,
signals were measured by a luminometer (Perkin-Elmer;
Shelton, CT). Baseline K-Ras activity prior to stimula-
tion with CXCL12 and CXCL11 was placed at zero; the
data presented represents the relative increases in K-Ras
activity due to stimulation. At least three independent
assays were performed for each cell line. The mean
absorbance ± one SD was plotted for each treatment
group.
Cell proliferation
Cell proliferation was assessed using a proliferation
assay (CellTiter-Glo, Promega; Madison, WI) based on
the quantification of ATP as previously described [27].
Cells were plated in 96-well plates at a density of 5 ×
10
3 cells per well and exposed to CXCL12 in serum-free
media for 72 h. Plates were incubated with CellTiter-
Glo reagent and luminescence was measured. At least
three independent cell proliferation assays were per-
formed. Baseline proliferation prior to stimulation with
CXCL12 and CXCL11 was placed at zero and the
results show the relative increases due to stimulation.
The mean absorbance ± one SD was plotted for each
treatment group.
Statistics
Statistical analysis of the data was performed using
unpaired Student’s t-test. P values were two-sided and
values of < 0.05 were considered statistically significant.
Results
CXCR4 and CXCR7 are co-expressed in human pancreatic
cancers
To assess the clinical frequency of CXCR4 and CXCR7
co-expression, we performed immunohistochemical
(IHC) staining in 51 FFPE human pancreatic cancer spe-
cimens. IHC demonstrated high frequency of CXCR4
and CXCR7 co-expression in these samples: 37 showed
double staining, 5 showed single staining, while 9 had
no staining. Representative IHC of CXCR4 and CXCR7
expression for three different patient samples are pre-
sented in Figure 1. For each patient sample, the section
stained with the CXCR4 antibody and the corresponding
CXCR7 section are immediately adjacent slices of the
F F P Et i s s u e .W eh a v ep r e v i o u s l ys h o w nt h ea b s e n c eo f
receptor staining in normal human pancreatic tissue
samples with an increase in staining intensity over
tumor stage [24].
CXCR4 and CXCR7 expression was assessed in 7 pan-
creatic cancer cell lines by immunoblotting. All cell
l i n e se x p r e s s e db o t hC X C R 4a n dC X C R 7 ,e x c e p tf o r
BxPC and SU.86.86 which lack CXCR4 (Figure 2). Our
results showing no CXCR7 expression in HT29 colon
cancer cells, which were utilized as a negative control,
are consistent with published reports [22,28]. We
selected PANC-1, MiaPaCa2, and FG cells for further
investigation.
CXCR4 and CXCR7 mediate the activation of the MAPK
pathway
We exposed PANC-1 and MiaPaCa2 cells to CXCL12,
which induced an increase in ERK phosphorylation in
agreement with our previous results [26]. Then, through
the use of CXCL11, we demonstrated that CXCR7-
mediated signaling alone cana l s oi n c r e a s eE R Kp h o s -
phorylation (Figure 3a). By using CXCL12 and CXCL11,
we show that both CXCR4 and CXCR7 can mediate
ERK phosphorylation in cells co-expressing these
receptors.
To further elucidate which receptor(s) mediate
CXCL12-driven ERK phosphorylation, we performed
CXCR4 or CXCR7 knockdown in PANC-1 cells (Figure
3b). Following knockdown, cells were exposed to
CXCL12 (Figure 3c). CXCR7 knockdown was required
to attenuate CXCL12-driven ERK phosphorylation. Our
results suggest that CXCR7-mediated signaling can reg-
ulate CXCL12-driven ERK phosphorylation in cells co-
expressing CXCR4/CXCR7.
CXCR4 signaling is required for the CXCL12-induced
increase in K-ras activity
We next sought to determine whether CXCR4 or
CXCR7 signaling targeted K-Ras, a known regulator of
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observed increased K-Ras activity in PANC-1 cells fol-
lowing exposure to CXCL12 but not to the CXCR7
ligand CXCL11 (Figure 4a). To further validate CXCR4
as the receptor involved in the CXCL12-driven change
in K-Ras activity, we again knocked down CXCR4 and
CXCR7 expression in the cells prior to CXCL12 stimu-
lation. We observed that CXCR4 knockdown, but not
CXCR7, blocked CXCL12-induced changes in K-Ras
activity (Figrue 4b). This supports our finding in Figure
4a that stimulating CXCR7 alone does not activate K-
ras activity. We concluded that CXCL12-driven
increases in K-Ras activity are mediated by CXCR4.
To directly assess the role of K-Ras in CXCL12 signal-
ing, we knocked down KRAS using siRNA and then
exposed pancreatic cancer cell lines to CXCL12. We
observed that KRAS knockdown greatly reduced
CXCL12-driven ERK1/2 phosphorylation (Figure 5).
These results support the involvement of K-Ras in
CXCL12-driven ERK phosphorylation in pancreatic can-
cer cells. Since the reduction of ERK1/2 phosphorylation
after KRAS knockdown could be attributed to oncogene
addiction due to a dysregulated signaling pathway [29],
we tested for this condition by exposing cells to EGF
after KRAS knockdown and found that our results are
unique to CXCL12 when compared to EGF and suggest
the absence of an oncogene addiction phenotype in cells
harboring mutant KRAS (Figure 5).
Signaling through CXCR4 and CXCR7 is b-arrestin-2-
dependent
We sought to determine whether b-arrestin-2 is
required for CXCR4 and CXCR7 signaling to the MAPK
pathway. We treated cells with both CXCL12 and
Figure 1 CXCR4 and CXCR7 expression in human formalin-fixed paraffin-embedded pancreatic cancer specimens. Pancreatic cancer
tissue was obtained from patients who had undergone resection for pancreatic adenocarcinoma with Institutional Review Board approval. Tissue
blocks were sectioned (5 μm) and deparaffinized with xylene. Antigen retrieval was performed and one section was incubated with the anti-
CXCR4 antibody and the next consecutive section from the same tissue block was incubated with the anti-CXCR7 antibody.
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using siRNA attenuated CXCL12 and CXCL11-driven
ERK phosphorylation indicating that b-arrestin-2 med-
iates CXCR4 and CXCR7 signaling to the MAPK path-
way (Figure 6).
CXCL12 drives an increase in cell proliferation
To determine if CXCL12 exposure results in changes in
pancreatic cancer cell proliferation, we exposed cells to
CXCL12 and CXCL11 for 72 h. We observed increased
cell proliferation. To ascertain which receptor(s)
mediated this increase in cell proliferation, we per-
formed CXCR4 and CXCR7 knockdown and once again
examined proliferation after 72 h. In the PANC-1 cell
line CXCR4 knockdown did not block CXCL12-
mediated changes in proliferation, but CXCR7 knock-
down did (Figrue 7). Opposite results were obtained for
the FG cell line. These results indicate that both CXCR4
and CXCR7 can mediate CXCL12-driven proliferation.
The mechanism by which this occurs still needs to be
elucidated.
Figure 2 CXCR4 and CXCR7 expression in pancreatic cancer
cell lines. Immunoblotting was performed for CXCR4 and CXCR7
protein expression in established human pancreatic cancer cell lines.
HT29 colon cancer cells were used as a negative control for CXCR7
expression. GAPDH was used as a loading control.
Figure 3 The effect of CXCL12 exposure on MAPK signaling. a) Pancreatic cancer cells PANC-1 and MiaPaCa2 were serum-starved and then
exposed to CXCL12 (100 ng/ml) and CXCL11 (200 ng/ml) over a range of time periods (5 min to 1 h). Immunoblotting was performed for
phosphorylated ERK1/2. Total ERK1/2 and GAPDH were used as loading controls. b) PANC-1 cells were transfected with control, CXCR4, or CXCR7
siRNA (100 nM) using RNAiMAX (10 μl). The immunoblots verify down-regulation of CXCR4 and CXCR7 expression. c) Following transfection, the
cells were serum-starved and then exposed to CXCL12 (100 ng/ml). Immunoblotting was performed for phospho-ERK1/2. Total ERK1/2 and
GAPDH were used as loading controls.
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Chemokines regulate the chemotactic responses of cells
that are essential for organogenesis and immunity
through the orchestration of cell movement from one
location to another [30-32]. Cancer cells have misappro-
priated these regulatory mechanisms to stimulate their
own growth, invasion, and metastasis. Numerous studies
now implicate chemokines and their corresponding
receptors in the invasive phenotype of many cancers [1].
In particular, the CXCL12-CXCR4 axis has been well
studied in gastrointestinal malignancies, but recent
reports suggest that downstream effects once attributed
to CXCR4 may also be secondary to CXCR7, an alter-
nate or second receptor for CXCL12. As a result, we
examined CXCL12 activity in pancreatic cancer cell
lines. Among several novel discoveries in this investiga-
tion, we identified high frequency of CXCR4/CXCR7
co-expression in human pancreatic cancer tissues and
cell lines.
Chemokine CXCL12 is characteristically expressed in
select tissues,[2] but may also be expressed via an autocrine
feedback loop mechanism in pancreatic cancer cells [7]. As
such, the resources for CXCL12 to activate CXCR4 or
CXCR7-mediated signaling pathways are present. Since
our studies target pancreatic cancer, we examined CXCL12
signaling within the framework of K-Ras. The gene encod-
ing KRAS is frequently mutated in patients with pancreatic
Figure 4 K-Ras activity in response to CXCL12 exposure.a )
Pancreatic cancer cells were serum-starved and then exposed to
CXCL12 (100 ng/ml) and CXCL11 (200 ng/ml) for 15 min. Whole cell
lysates were assessed for K-Ras activity using a Raf pull-down assay.
b) Cells were transfected with control, CXCR4, or CXCR7 siRNA (100
nM). Following serum-starvation cells were treated with CXCL12
(100 ng/ml) for 15 min. K-Ras activity was normalized to each
untreated baseline level; and relative increases are depicted. The
mean absorbance ± one SD was plotted for each treatment group.
* designates p < 0.05.
Figure 5 The effects of KRAS knockdown on ERK
phosphorylation following CXCL12 treatment. Pancreatic cancer
cells, FG and PANC-1 (left and right immunoblots respectively) were
transfected with control or KRAS siRNA (100 nM). Cells were serum-
starved and then exposed to CXCL12 (100 ng/ml) or EGF (100 ng/
ml) for 15 min. Immunoblotting was performed for K-Ras and
phospho-ERK1/2. Total ERK1/2 and GAPDH were used as loading
controls.
Figure 6 b-arrestin-2’s role in CXCR4 and CXCR7-driven ERK
phosphorylation. PANC-1 cells were transfected with control or b-
arrestin-2 siRNA (100 nM) using RNAiMAX (10 μl). Cells were serum-
starved and then exposed to CXCL12 (100 ng/ml) or CXCL11 (200
ng/ml) for 15 min. The immunoblot shows b-arrestin-2 and
phospho-ERK1/2 expression with total ERK1/2 and GAPDH serving
as loading controls.
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bute to the pathogenesis and progression of this cancer
[33,34]. Here, we made several novel observations regard-
ing K-Ras. First, we discovered that pancreatic cancer cells
co-expressing CXCR4/CXCR7 had increased levels of ERK
phosphorylation and K-Ras activity when exposed to
CXCL12. These CXCL12-induced increases in K-Ras activ-
ity were not observed with other ligands in endometrial
and pancreatic cancer cells harboring mutant KRAS
[35,36]. Our results, therefore, suggest that CXCL12 may
hyperactivate K-Ras activity levels even though there is
baseline mutant-derived K-Ras activity. Second, we
observed that CXCR4, rather than CXCR7, was the recep-
tor that regulated this response. GPCRs can signal through
a canonical or non-canonical pathway, activation of K-Ras
may occur via a CXCR4-mediated activation of the canoni-
cal GPCR pathway [37-39]. CXCR7 on the other hand sig-
nals through the non-canonical pathway [39], which
explains why CXCR7 activation leads to ERK1/2 phosphor-
ylation but not an increase in K-Ras activity. Β-arrestin-2 is
an important member of either pathway, and we show that
its knockdown blocks ERK phosphorylation. Third, we
determined that CXCL12-driven increases in cancer cell
proliferation can occur through either receptor and hence
either signaling pathway.
Specific inhibitors to CXCR4 and CXCR7 are cur-
rently unavailable for clinical use. AMD3100 was
believed to selectively bind and antagonize CXCR4
activity [40,41]. Derivatives of AMD3100 are also under
investigation for their effects on cancer cells [42]. A
recent study has demonstrated that AMD3100 specifi-
cally binds to and activates CXCR7 [41]. Therefore, in
contrast to its antagonism of the CXCL12-CXCR4 inter-
action, AMD3100 positively modulates CXCL12 effects
and binding to CXCR7.
Conclusion
In summary, we report that CXCR4 and CXCR7 are co-
expressed with high frequency in human pancreatic can-
cer specimens and cell lines. CXCR4 and CXCR7 signal-
ing is b-arrestin-2-dependent and controls CXCL12
signals to the MAPK pathway. CXCL12 activates both
canonical and non-canonical GPCR pathways in pan-
creatic cancer cell lines. This has functional significance
in that we show signaling through either pathway leads
to an increase in cell proliferation upon exposure to
CXCL12. Hence our study suggests that efforts to thera-
peutically target CXCL12 signaling in pancreatic cancer
should be focused at the level of the ligand to account
for both CXCR4 and CXCR7 activity.
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